Biodegradable in-situ forming implants and methods of producing the same

{
  "publication_number": "US5278201A",
  "country": "US",
  "kind": "A",
  "title": "Biodegradable in-situ forming implants and methods of producing the same",
  "abstract": "A biodegradable polymer is provided for use in providing syringeable, in-situ forming, solid biodegradable implants for animals. The polymer is placed into the animal in liquid form and cures to form the implant in-situ. A thermoplastic system to form said implant comprises the steps of dissolving a non-reactive polymer in biocompatible solvent to form a liquid, placing the liquid within the animal, and allowing the solvent to dissipate to produce the implant. An alternative, thermosetting system comprises mixing together effective amounts of a liquid acrylic ester terminated, biodegradable prepolymer and a curing agent, placing the liquid mixture within an animal and allowing the prepolymer to cure to form the implant. Both systems provide a syringeable, solid biodegradable delivery system by the addition of an effective level of biologically active agent to the liquid before injection into the body.",
  "claims": [
    "1. A pharmaceutical composition for forming a solid or coagulated biodegradable implant in-situ within a body, comprising a liquid solution of a non-reactive, biocompatible, pharmaceutically acceptable thermoplastic linear polymer that is water-insoluble and is biodegradable by simple or enzymatically catalyzed hydrolysis, and a pharmaceutically acceptable biocompatible solvent that is water-soluble, wherein the concentrations and formulas of said polymer and said solvent in said solution are effective to form said implant in-situ when said solution contacts body fluid.",
    "2. A pharmaceutical composition for forming a solid or coagulated biodegradable implant in-situ within a body, comprising a liquid solution of a non-reactive, biocompatible, pharmaceutically acceptable, thermoplastic linear polymer that is water-insoluble and a pharmaceutically acceptable biocompatible solvent that is water-soluble, wherein the concentrations and formulas of said polymer and said solvent in said solution are effective to form said implant in situ when said solution contacts body fluid; and wherein said polymer is selected from the group consisting essentially of polylactides, polyglycolides, polycaprolactones, polydioxannones, polycarbonates, polyhydroxybutyrates, polyalkyene oxalates, polyanhydrides, polyamides, polyesteramides, polyurethanes, polyacetals, polyketals, polyorthocarbonates, polyphosphazenes, polyhydroxyvalerates, polyalkylene succinates, poly(malic acid), poly(amino acids), chitin, chitosan, polyorthoesters, and copolymers, terpolymers and combinations and mixtures thereof.",
    "3. The composition of claim 2, wherein said polymer is selected from the group consisting essentially of polylactides, polycaprolactones and copolymers thereof with glycolide.",
    "4. The composition of claim 2, wherein said solvent is selected from the group consisting essentially of N-methyl-2-pyrrolidone, ethanol, propylene glycol, 2-pyrrolidone, acetone, methyl acetate, ethyl acetate, methyl ethyl ketone, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, caprolactam, decylmethylsulfoxide, oleic acid and 1-dodecylazacycloheptan-2-one and combinations and mixtures thereof.",
    "5. The composition of claim 2, wherein said solvent is selected from the group consisting essentially of N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethyl sulfoxide and acetone, and a combination or mixture thereof.",
    "6. The composition of claim 2, and further comprising an effective amount of a biologically active agent.",
    "7. The pharmaceutical composition according to claim 2, wherein the concentrations and formulas of said polymer and said solvent are effective to form a space filling implant when said composition is inserted into a site within the body.",
    "8. The pharmaceutical composition according to claim 3, wherein the weight % of said polymer in said solution is between about 20% and 75%.",
    "9. A pharmaceutical kit suitable for in situ formation of a biodegradable implant in a body, which comprises: A) a solution of a biodegradable, biocompatible, pharmaceutically acceptable thermoplastic polymer that is water-insoluble and a pharmaceutically acceptable solvent that is water-soluble, wherein the concentrations and formulas of the polymer and the solvent in the solution are effective to form an implant in situ when said solution contacts body fluid and wherein said polymer is selected from the group consisting essentially of polylactides, polyglycolides, polycaprolactones, polydioxannones, polycarbonates, polyhydroxybutyrates, polyalkyene oxalates, polyanhydrides, polyamides, polyesteramides, polyurethanes, polyacetals, polyketals, polyorthocarbonates, polyphosphazenes, polyhydroxyvalerates, polyalkylene succinates, poly(malic acid), poly(amino acids), chitin, chitosan, polyorthoesters, and copolymers, terpolymers and combinations and mixtures thereof; and, B) a device containing said solution, said device having an outlet for the solution, an ejector for expelling the solution through the outlet and a hollow tube fitted to the outlet for inserting the solution into a site of the body such that the solution can form an implant in situ at said site.",
    "10. The pharmaceutical kit according to claim 9, further comprising a biologically active agent dissolved or dispersed within said solution.",
    "11. The pharmaceutical kit according to claim 9, wherein said concentrations and formulas of said polymer and said solvent in said solution contained within said device are effective to form an implant in situ when the solution contacts body fluid.",
    "12. The pharmaceutical kit according to claim 9, wherein said concentrations and formulas of the polymer and the organic solvent are effective to form a space filling implant when the solution is inserted into said site.",
    "13. The pharmaceutical kit according to claim 9, wherein said polymer is selected from the group consisting of polylactides, polycaprolactones and copolymers thereof with glycolide.",
    "14. The composition of claim 1, wherein said solvent is selected from the group consisting essentially of N-methyl-2-pyrrolidone, ethanol, propylene glycol, 2-pyrrolidone, acetone, methyl acetate, ethyl acetate, methyl ethyl ketone, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran, caprolactam, decylmethylsulfoxide, oleic acid and 1-dodecylazacycloheptan-2-one and combinations and mixtures thereof.",
    "15. The composition of claim 1, wherein said solvent is selected from the group consisting essentially of N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethyl sulfoxide and acetone, and a combination or mixture thereof.",
    "16. The composition of claim 1, further comprising an effective amount of a biologically active agent.",
    "17. The pharmaceutical composition according to claim 1, wherein the concentrations and formulas of said polymer and said solvent are effective to form a space filling implant when said composition is inserted into a site within the body.",
    "18. A pharmaceutical kit suitable for in-situ formation of a biodegradable implant in a body, which comprises: A) a solution of a biocompatible, pharmaceutically acceptable thermoplastic polymer that is water-insoluble and is biodegradable by a simple or enzymatically catalyzed hydrolysis, and a pharmaceutically acceptable solvent that is water-soluble, wherein the concentrations and formulas of the polymer and the solvent in the solution are effective to form an implant in-situ when said solution contacts body fluid; and, B) a device containing said solution, said device having an outlet for the solution, an ejector for expelling the solution through the outlet and a hollow tube fitted to the outlet for inserting the solution into a site of the body such that the solution can form an implant in-situ at said site.",
    "19. The pharmaceutical kit according to claim 18, further comprising a biologically active agent dissolved or dispersed within said solution.",
    "20. The pharmaceutical kit according to claim 18, wherein said concentrations and formulas of said polymer and said solvent in said solution contained within said device are effective to form an implant in situ when the solution contacts body fluid.",
    "21. The pharmaceutical kit according to claim 18, wherein said concentrations and formulas of the polymer and the organic solvent are effective to form a space filling implant when the solution is inserted into said site."
  ],
  "description_excerpt": "This application is a division of application Ser. No. 07/252,645, filed Oct. 3, 1988, now U.S. Pat. No. 4,938,763.\n\nThe present invention relates to a method and composition for producing biodegradable polymers, and more particularly to the use of such polymers for providing syringeable, in-situ forming, solid, biodegradable implants.\n\nBiodegradable polymers have been used for many years in medical applications. These include sutures, surgical clips, staples, implants, and drug delivery systems. The majority of these biodegradable polymers have been thermoplastic materials based upon glycolide, lactide, ε-caprolactone, and copolymers thereof. Typical examples are the polyglycolide sutures described in U.S. Pat. No. 3,297,033 to Schmitt, the poly(L-lactide-co-glycolide) sutures described in U.S. Pat. No. 3,636,956 to Schneider, the poly(L-lactide-co-glycolide) surgical clips and staples described in U.S. Pat. No. 4,523,591 to Kaplan et al., and the drug-delivery systems described in U.S. Pat. No. 3,773,919 to Boswell et al., U.S. Pat. No. 3,887,699 to Yolles, U.S. Pat. No. 4,155,992 to Schmitt, U.S. Pat. No. 4,379,138 to Pitt et al., and U.S. Pat. Nos. 4,130,639 and 4,186,189 to Shalaby et al.\n\nAll of the biodegradable polymers described in these patents are thermoplastic materials. Consequently, they can be heated and formed into various shapes such as fibers, clips, staples, pins, films, etc. Only when heated above their melting point do these polymers become liquid. During their normal use, they are solids.",
  "cpc": [
    "A61K 9/0024",
    "A61F 2/00",
    "A61F 2002/30062",
    "A61F 2002/30583",
    "A61F 2210/0004",
    "A61F 2210/0085",
    "A61K 47/34",
    "A61L 15/44",
    "A61L 15/62",
    "A61L 2300/25",
    "A61L 2300/252",
    "A61L 2300/404",
    "A61L 2300/406",
    "A61L 2300/41",
    "A61L 2300/604",
    "A61L 24/0015",
    "A61L 24/0026",
    "A61L 24/0042",
    "A61L 24/046",
    "A61L 24/06",
    "A61L 26/0019",
    "A61L 26/0066",
    "A61L 26/0076",
    "A61L 26/009",
    "A61L 27/16",
    "A61L 27/18",
    "A61L 27/26",
    "A61L 27/34",
    "A61L 27/50",
    "A61L 27/54",
    "A61L 27/58",
    "Y10S 525/937"
  ],
  "ipc": [
    "A61F 2/00",
    "A61K 47/34",
    "A61K 9/00",
    "A61K 9/22",
    "A61L 15/44",
    "A61L 15/62",
    "A61L 24/00",
    "A61L 24/04",
    "A61L 24/06",
    "A61L 26/00",
    "A61L 27/00",
    "A61L 27/16",
    "A61L 27/18",
    "A61L 27/26",
    "A61L 27/34",
    "A61L 27/50",
    "A61L 27/54",
    "A61L 27/58"
  ],
  "assignees": [
    "Atrix Laboratories Inc"
  ],
  "inventors": [
    "Richard L. Dunn",
    "James P. English",
    "Donald R. Cowsar",
    "David P. Vanderbilt"
  ],
  "filing_date": "1990-04-24",
  "publication_date": "1994-01-11",
  "grant_date": "1994-01-11",
  "priority_date": "1988-10-03",
  "application_number": "US-51378290-A",
  "family_id": "22956926",
  "cited_by_count": 608,
  "citations": [
    "US2155658A",
    "US3068188A",
    "US3218283A",
    "US3887699A",
    "US3939111A",
    "US4161948A",
    "US4447562A",
    "US4631188A",
    "US4745160A",
    "US4767627A",
    "US4920203A"
  ]
}